ArticleArthritis care & research2026
Prevalence of Arthritis-Attributable Activity Limitations - United States, 2023.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe objectives of this study were (1) to estimate the 2023 prevalence of arthritis-attributable activity limitations (AAAL) among US adults with arthritis overall and by selected sociodemographic and health characteristics and (2) to assess progress toward the Healthy People 2030 objective to reduce AAAL by describing the change in AAAL prevalence from 2019 to 2023.
methodsCross-sectional data from the 2019 and 2023 National Health Interview Survey were used. Unadjusted and age-standardized prevalences of AAAL in 2023 were estimated overall and by sociodemographic and health characteristics among US adults who reported having doctor-diagnosed arthritis. Differences in the prevalence of AAAL by sociodemographic and health characteristics were assessed using t-tests. The overall unadjusted and age-standardized prevalences of AAAL in 2019 were estimated and tested against 2023 estimates for differences by survey year (2019 and 2023).
resultsDuring 2023, an estimated 24.8 million adults with arthritis reported having an activity limitation (age-adjusted prevalence, 47.8%; 95% confidence interval [CI], 45.0%-50.7%). There were significant differences in age-adjusted AAAL prevalence by sociodemographic and health characteristics. Although there was a decline in the estimated age-adjusted prevalence of AAAL from 2019 (49.2%; 95% CI, 46.7%-51.6%) to 2023, this change was not statistically significant.
conclusionAbout half of US adults with doctor-diagnosed arthritis report activity limitations due to arthritis, and the Healthy People 2030 objective for an AAAL prevalence of 46.8% has not been met. Organizations, working individually or as partners, to implement arthritis-appropriate evidence-based interventions could contribute to achieving the Healthy People 2030 goal of reducing AAAL among US adults with arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.